Highest-materiality recent filing
VitaSpring Biomedical names Jing-Zhou Chen CEO/CFO, Shao-Hsiang Shih Chairman; Lai resigns
Ssu-Chuan Lai resigned as Chairperson, CEO, President, CFO, Secretary, and director effective 11:58 p.m. PT Sept 7, 2026; no disagreement cited.
VitaSpring Biomedical appoints JP Centurion as new independent auditor
Engaged JP Centurion & Partners PLT as independent registered public accounting firm effective August 19, 2025.
Auditor TAAD resigns; four directors/officers exit; Dr. Lai appointed CEO/CFO/Chair
TAAD LLP resigned as independent auditor effective Aug 5, 2025; no disagreements or reportable events.
CEO and Chairman of VitaSpring face multiple Taiwan legal proceedings including indictments
CEO Kao and Chairman Chu involved in criminal civil cases for unauthorized IP use, violations of Taiwan's Pharmaceutical Affairs Act.
Kho & Patel resigned as auditor on Jan 17, 2023; no disagreements or reportable events.
CEO Chu Pao-Chi resigns; Kao Cheng-Hsiang appointed CEO and retains Secretary role
Chu Pao-Chi resigned as CEO effective August 7, 2020.
Effective at 11:57 p.m. Pacific Time on September 7, 2026, Mr. Shih was appointed Chairman of the Board, to serve at the pleasure of the Board.
Effective at 11:58 p.m. Pacific Time on September 7, 2026, immediately following the election of her successor as a director and the appointment of her successor officers as described in Items 5.02(c) and (d) below, Dr. Ssu-Chuan Lai resigned from her positions as Chairperson of the Board, Chief Executive Officer, President, Chief Financial Officer, and Secretary of the Company, and as a member of the Board.
Effective at 11:57 p.m. Pacific Time on September 7, 2026, Dr. Ssu-Chuan Lai, as the sole director then in office, appointed Jing-Zhou Chen as the Company’s Chief Executive Officer, President, Chief Financial Officer, and Secretary, to serve at the pleasure of the Board and until his successor is duly appointed and qualified, or until his earlier death, resignation or removal.
Effective at 11:56 p.m. Pacific Time on September 7, 2026, Ssu-Chuan Lai, as the sole director then in office, elected Shao-Hsiang Shih to serve as a director of the Company, to hold office until the next annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
Max materiality 0.75 · Median 0.60 · Most common event other_material